Hepcidin, but not erythropoietin, levels are associated with decreased testosterone in men with immune-mediated inflammatory rheumatic diseases and anemia
Open Access
- 27 August 2026
- journal article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (10) , 584-589
Abstract
Background. Anemia and decreased testosterone levels in men are common comorbidities in immune-mediated inflammatory rheumatic diseases (IIRDs). Aim. To evaluate the relationship between total testosterone (TT) and hepcidin and erythropoietin levels in men with IIRDs and anemia. Materials and methods. A cross-sectional study included 136 men with IIRDs (66 patients with rheumatoid arthritis – RA, 44 with ankylosing spondylitis – AS, 26 with psoriatic arthritis – PsA) and anemia. A correlation analysis was performed for all quantitative parameters with TT, hepcidin, and erythropoietin levels, as well as a comparative subgroup analysis between patients with normal and reduced (≤12.0 nmol/L) TT. Results. In RA, AS and PsA and anemia, the subgroup with reduced TT was characterized by comparable levels of hemoglobin and erythropoietin compared to patients without androgen deficiency. The hepcidin level in RA patients with testosterone deficiency was significantly higher (38.0 [31.8; 39.1] ng/ml versus 21.5 [7.8; 30.5] ng/ml; p0.001) in RA patients. Among patients with AS, the subgroup with reduced TT was characterized by comparable levels of hepcidin (29.2 [6.5; 34.1] ng/ml versus 31.3 [27.2; 34.9] ng/ml; p=0.3). Among patients with PsA, the subgroup with reduced TT levels was characterized by higher hepcidin levels in testosterone deficiency (37.0 [29.9; 38.7] ng/ml vs. 25.8 [4.6; 33.0] ng/ml; p=0.009). Conclusion. The obtained results indicate no relationship between TT levels and erythropoietin in patients with RA, AS, and PsA and concomitant anemia, while reduced TT levels were associated with increased hepcidin levels in RA and PsA, and are most likely due to high IIRD activity.This publication has 17 references indexed in Scilit:
- Current Landscape of Hepcidin Therapeutics2025
- Anemia and testosterone deficiency risk: insights from NHANES data analysis and a Mendelian randomization analysisThe Aging Male, 2024
- Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With HypogonadismJAMA Network Open, 2023
- Mechanisms controlling cellular and systemic iron homeostasisNature Reviews Molecular Cell Biology, 2023
- Präoperative Anämie beim RheumatikerZeitschrift für Rheumatologie, 2022
- Anemia of inflammationBlood, 2019
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2018
- Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set PointThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2013
- Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced ErythrocytosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Hypoxic Induction of the Human Erythropoietin Gene: Cooperation between the Promoter and Enhancer, Each of Which Contains Steroid Receptor Response ElementsMolecular and Cellular Biology, 1992